HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-stage study tested an experimental drug called BLU-222 in 50 people with advanced solid tumors (like breast, ovarian, or stomach cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The st…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
Radioactive drug trial for advanced cancers halted early
Disease control TerminatedThis study tested a new radioactive drug, [225Ac]-FPI-1434, in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited. It involved 78 partic…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 17, 2026 06:47 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Early trial of targeted combo for rare breast cancer subtype ends early
Disease control TerminatedThis early-phase study tested a new drug (infigratinib) combined with tamoxifen for people with a specific advanced breast cancer that is hormone receptor-positive, HER2-negative, and has changes in the FGFR gene. The main goal was to find a safe dose by monitoring side effects. …
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated May 06, 2026 16:03 UTC